Cassava Sciences’ beleaguered investigational Alzheimer’s therapy is in two phase 3 studies.
An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped?
Cassava Sciences’ beleaguered investigational Alzheimer’s therapy is in two phase 3 studies.
